Imatinib is an oral treatment for chronic myelogenous leukemia (CML), an uncommon type of cancer of the bone marrow, which arises from a pluripotent hematopoietic stem cell that has undergone a reciprocal translocation between the breakpoint cluster region protein (Bcr) gene on chromosome 22 and the Abelson tyrosine-protein kinase 1 (Abl1) proto-oncogene on chromosome 9. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.